Press Releases

Press Releases

Veriskin is at the forefront of the most accurate skin cancer screening technology.
Here you can find out what the company is up to.

Press Release

Veriskin Ranked Most Fundable Company by Pepperdine Graziadio Business School

Effective date:

Veriskin, Inc. is thrilled to announce that it achieved recognition on the Pepperdine Graziadio Business School’s fourth annual Most Fundable Companies® List. Veriskin competed against over 3,300 of early-stage US companies to be named one of 16 companies in total. The Most Fundable Companies initiative aims to educate founders on the investor diligence process and recognize exceptional entrepreneurs who are solving today’s problems with inventive solutions and are also seeking investment capital to fuel their company's growth.


Veriskin Raises Additional Capital for Seed-1 Round

Effective date:

Veriskin has completed a 2nd closing of the ongoing Seed-I round. Participating investors include Frontier Angels and TIE SoCal Angels.


Veriskin Wins the 5th Annual Glendale Tech Week Pitchfest Competition

Effective date:

Pitchfest is one of many events lined up for the City of Glendale’s fifth annual Glendale Tech Week. Veriskin has won a prize package of $150,000.


Veriskin Raises Additional Capital for Seed-1 Round

Effective date:

Veriskin has completed a 2nd closing of the ongoing Seed-I round. Participating investors include Frontier Angels and TIE SoCal Angels.


Veriskin closes Seed-I round

Effective date:

Veriskin, Inc. has completed initial closing of Series Seed-1 Preferred Equity Round led by Pasadena Angels and Ariel South East Angel Partners with participation of Pasadena Angels Fund 1.


FDA Recognizes the Novelty of Veriskin's Skin Cancer Detection Technology

Effective date:

FDA grants a Breakthrough Device Designation Status to the TruScore device. The FDA's Breakthrough Device Program is intended to expedite the development and prioritize the review of certain medical devices that provide for more effective treatment or diagnosis of life-threatening or irreversibly debilitating diseases or conditions.


Veriskin Selected as Connect 2020 Cool Company. Joins a Group of San Diego’s 30 Top-Performing Life Sciences Startups

Effective date:

Cool Companies is an annual capital program designed to match San Diego’s best technology and life sciences startups ready to raise Series A — with quality venture capital. The program selects top tier, local entrepreneurs raising institutional funding, and grants them opportunities for direct access to capital providers. The program regularly attracts over 200 VCs to the region annually. Since 2016, Cool Companies have raised over $400M, in just Series A institutional funding. Cool Companies 2020.




Veriskin Receives Funding Support from the NIH

Effective date:

Veriskin, Inc. has received a second $2M grant award from the National Cancer Institute. The NIH review panel cited an “outstanding application”, a “strong scientific premise” and was “highly enthusiastic” about the team. The funding will enable further development and clinical testing of the TruScore device.


A Key Patent Granted in Australia

Effective date:

IP Australia has approved Veriskin's application for a key patent that covers its core technology: TruScore Patent.


Veriskin Receives Special Invitation to LA BioMed Innovation Showcase 2018

Effective date:

Veriskin, Inc. scored top among 13 medical device companies selected to participate in LA BioMed Innovation Showcase 2018.


Veriskin Initiates 100+ Patient Clinical Study

Effective date:

Veriskin, Inc. has initiated a 100+ human clinical study to test the TruScore device. The IRB approved study is conducted by Palo Alto Medical Foundation (a division of Sutter Health).


Veriskin Invited to Present at TedX San Diego Innovation Alley

Effective date:

Veriskin, Inc. was invited to present at TedXs' Innovation Alley held in downtown San Diego that showecased 20 of San Diego’s most innovative companies and entrepreneurs. See event photos here.




Veriskin Receives NIH Grant to Pursue Skin Cancer Screening Technology

Effective date:

Veriskin, Inc. has been awarded a $1.875M grant by the National Institutes of Health to develop a novel technology for non-invasive skin cancer screening. The National Cancer Institute that issued the award cited “the exceptionally high impact that the proposed device is expected to make in the field of non-invasive skin cancer diagnostics”.